Antipsychotic Drugs Market By Drug Class (First-Generation Antipsychotics {Typical}, Second-Generation Antipsychotics {Atypical}, Third-Generation Antipsychotics), By Indication (Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Dementia, Alzheimer’s Disease, and Others), By Route of Administration (Oral, Injectable), By End-User (Hospital, Clinics, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Drug Class

• First-Generation Antipsychotics (Typical)
• Second-Generation Antipsychotics (Atypical)
• Third-Generation Antipsychotics

By Indication

• Schizophrenia
• Bipolar Disorder
• Major Depressive Disorder
• Dementia and Alzheimer’s Disease
• Others

By Route of Administration

• Oral
• Injectable

By End-User

• Hospitals
• Clinics
• Homecare Settings

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Johnson & Johnson
• Eli Lilly and Company
• AstraZeneca plc
• Bristol-Myers Squibb
• Pfizer Inc.
• Roche Holding AG
• Novartis International AG
• GlaxoSmithKline plc
• Otsuka Pharmaceutical Co. Ltd.
• Allergan plc
• H. Lundbeck A/S
• Sumitomo Pharma Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim GmbH
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited